Let’s get one thing straight: when a company beats analyst EPS estimates by 61%, the stock is supposed to go up.
On February 26, 2026, Catalyst Pharmaceuticals (NASDAQ: CPRX) reported Q4 adjusted EPS of $0.68 against a Zacks consensus of $0.42. Revenue came in at $152.6M — 9% above estimates. Full-year 2025 revenue hit $589M, up 19.8%, the fourth consecutive year of records. Operating margin: 43.8%. Free cash flow: $208.6M. Management guided 2026 revenue to $615-645M and called it with confidence.
The stock fell on the news. As of late March 2026, CPRX trades around $23-24, at roughly 10.8x forward earnings.
That reaction tells you more about how the market is ignoring this company than it does about the fundamentals. Almost no institutional analysts cover CPRX. The narrative hasn’t been written yet. There’s a binary patent event in May that’s keeping risk-averse money on the sidelines. And all of that creates a window that probably closes sometime in Q3 when Wall Street starts paying attention. We’ve seen this pattern before — dLocal crossed $1 billion in revenue and nobody noticed for months, or CRDO grew revenue 201% while trading 60% off its highs.
What Catalyst Actually Sells
Three FDA-approved drugs. One dominant, one growing fast, one fading.
FIRDAPSE (amifampridine) is the only FDA-approved treatment for Lambert-Eaton Myasthenic Syndrome (LEMS) — a rare autoimmune disease where the immune system attacks the neuromuscular junction, leaving patients unable to contract muscles properly. About 3,000-5,000 people in the U.S. have LEMS. Most of them depend on FIRDAPSE. It launched in 2018 and still grew 18.3% in Q4 2025. In 2026, management is guiding $435-450M in FIRDAPSE revenue — 21-26% growth, seven years post-launch.
That growth trajectory is unusual. It comes from lifecycle expansion: Catalyst is actively pursuing reimbursement and awareness for two FIRDAPSE sub-indications — Idiopathic LEMS (no known cancer trigger) and Cancer-Associated LEMS (LEMS that develops alongside small cell lung cancer). Both are underdiagnosed. The addressable patient population keeps expanding as neurologists get better at identifying the disease.
AGAMREE (vamorolone) is for Duchenne Muscular Dystrophy (DMD). About 15,000-20,000 boys and young men in the U.S. have DMD, a fatal genetic disease that destroys muscle tissue over time. The standard treatment is corticosteroids like prednisone — they help, but long-term use causes weight gain, bone loss, cataracts, and growth suppression in kids. AGAMREE is a dissociative steroid that suppresses DMD inflammation without the same metabolic side effects. Catalyst in-licensed it from Santhera Pharmaceuticals in 2023 for $210M. Q4 AGAMREE revenue was up 67.5% year-over-year. Management guides $140-150M in 2026, which would represent 20-28% growth over 2025.
FYCOMPA (perampanel) is an epilepsy drug from Eisai that Catalyst acquired in 2023. It lost patent exclusivity in May 2025 for tablets and December 2025 for the oral suspension. Three generics are already competing. Catalyst guides $40-45M in FYCOMPA revenue for 2026, and that number will continue declining. It’s not a catastrophe, but it’s a headwind they’re managing around.
The Numbers That Matter
Q4 2025:
- Revenue: $152.6M (+7.6% YoY; +9% vs. consensus of $140M)
- Adjusted EPS: $0.68 (vs. $0.42 consensus — 61% beat)
- FIRDAPSE growth: +18.3% YoY
- AGAMREE growth: +67.5% YoY
Full Year 2025:
- Total revenue: $589M (+19.8%)
- Net income: $214.3M (+30.8%)
- Operating margin: 43.8%
- EBITDA margin: 50.2%
- Diluted EPS: $1.68 (+28.2%)
- Free cash flow: $208.6M
Valuation snapshot (March 2026):
- Stock price: ~$23.40
- Market cap: ~$2.86B
- Enterprise value: ~$2.15B
- Trailing PE: 13.9x
- Forward PE: 10.8x
- Short interest: 8.49% of float (as of Feb 27, 2026)
- 52-week range: $19.05 – $26.58
- Analyst consensus target: $34-35 (+53% upside)
2026 guidance (issued Feb 26, 2026):
- Total revenues: $615-645M
- FIRDAPSE: $435-450M (21-26% growth)
- AGAMREE: $140-150M (20-28% growth)
- FYCOMPA: $40-45M (declining from patent cliff)
The Bull Case
FIRDAPSE is a durable monopoly still in mid-growth. Rare disease drugs with no meaningful competition and an expanding patient identification pipeline don’t come around often. FIRDAPSE has been on the market since 2018 and is still growing at 18%+ quarterly. When you calculate the known LEMS patient population against current FIRDAPSE revenues, there’s still significant room for penetration growth — particularly in the LEMS subtypes that neurologists are only now starting to routinely test for. The Cancer-Associated LEMS and Idiopathic LEMS expansion programs are multi-year revenue drivers that most analysts haven’t modeled aggressively.
AGAMREE is tracking to be a major second franchise. 67.5% growth in Q4 on a drug that launched commercially in 2023 is not a normal trajectory. The DMD space is undersupplied with effective, tolerable treatments. Catalyst paid $210M to in-license AGAMREE from Santhera — if it reaches $300M in annual revenue by 2028, that acquisition looks like a steal. The 2026 guidance of $140-150M is probably conservative given the current trend.
The valuation gap makes no sense given the fundamentals. CPRX trades at 10.8x forward earnings with 20%+ top-line growth and 50%+ operating margins. United Therapeutics (UTHR) — a comparable rare disease company — trades at 14x+. Intra-Cellular Therapies (ITCI) trades north of 30x. Catalyst is growing faster than either and trading cheaper than both. The only justification for the discount is the May patent trial. Remove that uncertainty and this stock re-rates materially.
Coverage expansion is coming. IBD’s Composite Rating hit 96. Zacks upgraded to Strong Buy. Citigroup raised its price target to $35. Formal institutional coverage is thin right now, which is exactly the kind of setup that precedes a re-rating once the story gets wider distribution. The retail investor community is barely aware this company exists.
The Bear Case
The Firdapse patent trial is the real overhang. On March 18, 2026, Catalyst filed an 8-K disclosing that a federal court in New Jersey pushed the FIRDAPSE patent bench trial from March 23 to May 18, 2026. The counterparty is Hetero USA, which wants to launch a generic amifampridine. If Hetero wins — meaning the court finds Catalyst’s patents invalid or not infringed — the FIRDAPSE franchise faces generic competition on a drug that generates $435-450M in 2026 revenue.
That scenario would be ugly. The stock would likely give back 40-50% fast. The 8.49% short interest is pricing this risk in. Anyone buying CPRX today is making an explicit bet on the patent outcome, whether they acknowledge it or not.
Concentration risk. FIRDAPSE accounts for roughly 70% of 2026 projected revenue. AGAMREE is growing fast but is still a $140M product. If FIRDAPSE gets generic competition, there’s no offsetting asset large enough to absorb the blow in the near term. AGAMREE would need to 3x over three years to compensate for a material FIRDAPSE hit.
Rare disease revenue ceilings are real. LEMS has somewhere between 3,000-5,000 diagnosed patients in the U.S. Catalyst can grow within that population by better identifying patients, but there’s a hard ceiling. The lifecycle expansion into LEMS subtypes buys years of growth, but eventually it moderates. AGAMREE in DMD has a larger patient pool — 15,000-20,000 — but it’s competing against entrenched steroid protocols that neurologists have used for decades.
FYCOMPA will keep declining. Three generics are eroding the tablet franchise now. The oral suspension went generic in December 2025. $40-45M is management’s floor estimate for 2026; actual could come in lower if penetration accelerates.
Catalysts to Watch
- May 18, 2026 — FIRDAPSE patent bench trial verdict. This is the binary event that determines whether the whole thesis plays out.
- May 6, 2026 — Q1 2026 earnings. Management will update on AGAMREE trajectory and whether the $615-645M guidance is on track.
- AGAMREE quarterly prints — Any quarter above $40M would push the annual run rate ahead of current guidance and force upward revisions.
- New acquisitions — $208M in annual free cash flow gives Catalyst serious firepower to add a third growth drug. An acquisition announcement could re-rate the stock independent of the patent outcome.
The Verdict
CPRX at $23-24 is a company growing revenue 20%+ per year with 50%+ operating margins trading at 10.8x forward earnings. The analyst consensus is $34-35. That gap almost entirely comes down to May 18.
If the patents hold — which management clearly believes, otherwise they wouldn’t be issuing $615-645M guidance with confidence — the current price looks like a meaningful discount to intrinsic value. Re-rating from 10.8x to 14-15x on 2026 earnings alone would put CPRX somewhere between $29 and $33, before any credit for AGAMREE compounding. That’s 20-40% upside from purely closing a valuation gap that exists only because of event risk.
If the patents fall, cut the position in half and reassess. The AGAMREE story is still intact, but FIRDAPSE generic competition changes the math materially.
For investors who can size the position appropriately and sit through a binary court outcome in May, the risk/reward at $23-24 is reasonable. For investors who can’t stomach that kind of event risk, wait until after May 18. You might pay 30-40% more if Catalyst wins, but you’ll be buying a clean story.
At 10.8x forward earnings on 20%+ growth with 50%+ margins, the market is effectively pricing in coin-flip odds of patent failure. Whether those odds are accurate is the entire question.
This is not financial advice. Do your own research. I hold no position in CPRX.